Foreign medicine has been negotiated by the health and Family Planning Commission. Is the next wave of Chinese medicine exclusive?

Source: a new round of bidding was launched on January 30, 2016, and domestic pharmaceutical enterprises were overwhelmed by volume procurement, second and even third bargaining And what about the drug price negotiations that the national health and Family Planning Commission has been preparing for foreign original research drugs? Yesterday, Ji Haiwei, senior vice president of GlaxoSmithKline, was interviewed by the media According to media reports such as Xinhuanet, the national drug price negotiation pilot has begun Xinhua reported as follows: it is reported that in the recent national drug price negotiation pilot, GlaxoSmithKline took a very positive attitude and fully cooperated with the government in this initiative In addition to commercial considerations, more from the standpoint of corporate responsibility to consider how to let more patients use high-quality innovative drugs Drug price negotiation includes not only price reduction, but also quantity improvement "GlaxoSmithKline will actively respond to and respond to environmental changes, launch a flexible pricing mechanism, and work with the Chinese government to help achieve a" healthy China "construction." Jihaiwei said It can be seen from this that the national health and Family Planning Commission has begun to conduct pilot negotiations on some foreign-funded original research drugs Previously, it was rumored that the first batch of national drug price negotiation targets had been set, with five varieties, namely, lenalidomide (new base medicine) for multiple myeloma and tenofovir dipivoxil (Gilead) for hepatitis B; Gefitinib (AstraZeneca), erlotinib (Roche pharmaceutical) and exetinib (Beida, Zhejiang) in the treatment of advanced non-small cell lung cancer did not include the varieties of GlaxoSmithKline According to GlaxoSmithKline's statement, GlaxoSmithKline participated in the treatment, and it is not known whether the negotiation catalogue has been expanded Obviously in this round of negotiations, GlaxoSmithKline's attitude is to reduce prices In this round of drug bidding frenzy, foreign drugs generally do not reduce prices, but GlaxoSmithKline is the initiative to reduce prices At the end of July 2015, GlaxoSmithKline executives said that GlaxoSmithKline would take the initiative to reduce the price of some of the original research drugs by 20% - 30% It is said that the effect of price reduction is that the non sales performance remains good, and sales in China are expected to achieve sustained and steady growth in 2016 In the national drug price negotiations, how much is the decline? The media did not disclose However, the positive price reduction attitude of GlaxoSmithKline has brought a lot of pressure to other foreign drugs entering the negotiation pilot GlaxoSmithKline has reduced its price, so do other enterprises? We have micro friends who understand the negotiation, and we look forward to your sharing with us When will exclusive Chinese patent medicines be discussed? Will Ningbo test water first? The varieties involved in the national negotiation mechanism are divided into clinical patent medicines, public health patent medicines and exclusive produced Chinese patent medicines According to the previous information, the negotiation on the original research drug is to be negotiated by the state, the exclusive traditional Chinese medicine is to be negotiated by each province, and the national drug price negotiation has been started Is the exclusive traditional Chinese medicine negotiation about to be started soon? Although there is no provincial bidding practice, Ningbo has taken the lead On January 18, Ningbo health and Family Planning Commission issued the notice of 2015 limited price purchase price negotiation of Chinese patent medicine in Ningbo public medical institutions community The scope of the second negotiation is mainly exclusive varieties and varieties of multiple manufacturers, 1022 in total, of which the proportion of exclusive varieties is more than 70%, 742 in total Famous for slashing the price of consumables, Ningbo, which created the Ningbo model, obviously aimed the reduced price of cannons at the exclusive Chinese patent medicine Although it is not clear when the exclusive Chinese patent medicine negotiation will start, as a national arrangement, the exclusive Chinese patent medicine negotiation is not far away After a round of bombing in Ningbo (perhaps also the water test in the early stage of the negotiation), the price prospect of the exclusive Chinese patent medicine negotiation is unimaginable Enterprises that are likely to be negotiated should be prepared Author: situ Yangming